These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 16307483)

  • 1. Inhibition of human kallikreins 5 and 7 by the serine protease inhibitor lympho-epithelial Kazal-type inhibitor (LEKTI).
    Schechter NM; Choi EJ; Wang ZM; Hanakawa Y; Stanley JR; Kang Y; Clayman GL; Jayakumar A
    Biol Chem; 2005 Nov; 386(11):1173-84. PubMed ID: 16307483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. hK5 and hK7, two serine proteinases abundant in human skin, are inhibited by LEKTI domain 6.
    Egelrud T; Brattsand M; Kreutzmann P; Walden M; Vitzithum K; Marx UC; Forssmann WG; Mägert HJ
    Br J Dermatol; 2005 Dec; 153(6):1200-3. PubMed ID: 16307658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LEKTI domain 15 is a functional Kazal-type proteinase inhibitor.
    Vitzithum K; Lauber T; Kreutzmann P; Schulz A; Sommerhoff CP; Rösch P; Marx UC
    Protein Expr Purif; 2008 Jan; 57(1):45-56. PubMed ID: 17936012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant production, purification and biochemical characterization of domain 6 of LEKTI: a temporary Kazal-type-related serine proteinase inhibitor.
    Kreutzmann P; Schulz A; Ständker L; Forssmann WG; Mägert HJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2004 Apr; 803(1):75-81. PubMed ID: 15026000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of LEKTI domains 6-9' in the baculovirus expression system: recombinant LEKTI domains 6-9' inhibit trypsin and subtilisin A.
    Jayakumar A; Kang Y; Mitsudo K; Henderson Y; Frederick MJ; Wang M; El-Naggar AK; Marx UC; Briggs K; Clayman GL
    Protein Expr Purif; 2004 May; 35(1):93-101. PubMed ID: 15039071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LEKTI-1 in sickness and in health.
    Roelandt T; Thys B; Heughebaert C; De Vroede A; De Paepe K; Roseeuw D; Rombaut B; Hachem JP
    Int J Cosmet Sci; 2009 Aug; 31(4):247-54. PubMed ID: 19467033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of serine proteinases plasmin, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: a kinetic analysis.
    Mitsudo K; Jayakumar A; Henderson Y; Frederick MJ; Kang Y; Wang M; El-Naggar AK; Clayman GL
    Biochemistry; 2003 Apr; 42(13):3874-81. PubMed ID: 12667078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New role for LEKTI in skin barrier formation: label-free quantitative proteomic identification of caspase 14 as a novel target for the protease inhibitor LEKTI.
    Bennett K; Callard R; Heywood W; Harper J; Jayakumar A; Clayman GL; Di WL; Mills K
    J Proteome Res; 2010 Aug; 9(8):4289-94. PubMed ID: 20533828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
    Meyer-Hoffert U; Wu Z; Schröder JM
    PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Consequences of C-terminal domains and N-terminal signal peptide deletions on LEKTI secretion, stability, and subcellular distribution.
    Jayakumar A; Kang Y; Henderson Y; Mitsudo K; Liu X; Briggs K; Wang M; Frederick MJ; El-Naggar AK; Bebök Z; Clayman GL
    Arch Biochem Biophys; 2005 Mar; 435(1):89-102. PubMed ID: 15680911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LEKTI proteolytic processing in human primary keratinocytes, tissue distribution and defective expression in Netherton syndrome.
    Bitoun E; Micheloni A; Lamant L; Bonnart C; Tartaglia-Polcini A; Cobbold C; Al Saati T; Mariotti F; Mazereeuw-Hautier J; Boralevi F; Hohl D; Harper J; Bodemer C; D'Alessio M; Hovnanian A
    Hum Mol Genet; 2003 Oct; 12(19):2417-30. PubMed ID: 12915442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between SPINK5 gene mutations and clinical manifestations in Netherton syndrome patients.
    Komatsu N; Saijoh K; Jayakumar A; Clayman GL; Tohyama M; Suga Y; Mizuno Y; Tsukamoto K; Taniuchi K; Takehara K; Diamandis EP
    J Invest Dermatol; 2008 May; 128(5):1148-59. PubMed ID: 17989726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
    Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
    Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A potential role for multiple tissue kallikrein serine proteases in epidermal desquamation.
    Borgoño CA; Michael IP; Komatsu N; Jayakumar A; Kapadia R; Clayman GL; Sotiropoulou G; Diamandis EP
    J Biol Chem; 2007 Feb; 282(6):3640-52. PubMed ID: 17158887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of human mast cell chymase by secretory leukocyte proteinase inhibitor: enhancement of the interaction by heparin.
    Walter M; Plotnick M; Schechter NM
    Arch Biochem Biophys; 1996 Mar; 327(1):81-8. PubMed ID: 8615699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients.
    Roedl D; Oji V; Buters JT; Behrendt H; Braun-Falco M
    J Dermatol Sci; 2011 Mar; 61(3):194-8. PubMed ID: 21251800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum.
    Ishida-Yamamoto A; Deraison C; Bonnart C; Bitoun E; Robinson R; O'Brien TJ; Wakamatsu K; Ohtsubo S; Takahashi H; Hashimoto Y; Dopping-Hepenstal PJ; McGrath JA; Iizuka H; Richard G; Hovnanian A
    J Invest Dermatol; 2005 Feb; 124(2):360-6. PubMed ID: 15675955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of human epidermal kallikrein 7 (hK7) synthesized directly in its native state in E. coli: insights into the atomic basis of its inhibition by LEKTI domain 6 (LD6).
    Fernández IS; Ständker L; Mägert HJ; Forssmann WG; Giménez-Gallego G; Romero A
    J Mol Biol; 2008 Apr; 377(5):1488-97. PubMed ID: 18329042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 420K LEKTI variant alters LEKTI proteolytic activation and results in protease deregulation: implications for atopic dermatitis.
    Fortugno P; Furio L; Teson M; Berretti M; El Hachem M; Zambruno G; Hovnanian A; D'Alessio M
    Hum Mol Genet; 2012 Oct; 21(19):4187-200. PubMed ID: 22730493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serine protease inhibitor lymphoepithelial Kazal type-related inhibitor tends to be decreased in atopic dermatitis.
    Roedl D; Traidl-Hoffmann C; Ring J; Behrendt H; Braun-Falco M
    J Eur Acad Dermatol Venereol; 2009 Nov; 23(11):1263-6. PubMed ID: 19522716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.